GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medesis Pharma SA (STU:76D) » Definitions » Gross-Profit-to-Asset %

Medesis Pharma (STU:76D) Gross-Profit-to-Asset % : -33.93% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Medesis Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Medesis Pharma's annualized Gross Profit for the quarter that ended in Jun. 2024 was €-0.68 Mil. Medesis Pharma's average Total Assets over the quarter that ended in Jun. 2024 was €2.02 Mil. Therefore, Medesis Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was -33.93%.


Medesis Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Medesis Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medesis Pharma Gross-Profit-to-Asset % Chart

Medesis Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial -11.98 -64.05 -84.04 -70.65 -138.73

Medesis Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -66.71 -79.97 -103.54 -188.87 -33.93

Competitive Comparison of Medesis Pharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Medesis Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medesis Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medesis Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Medesis Pharma's Gross-Profit-to-Asset % falls into.


;
;

Medesis Pharma Gross-Profit-to-Asset % Calculation

Medesis Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-2.665/( (1.916+1.926)/ 2 )
=-2.665/1.921
=-138.73 %

Medesis Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=-0.684/( (1.926+2.106)/ 2 )
=-0.684/2.016
=-33.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Medesis Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Medesis Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medesis Pharma Business Description

Traded in Other Exchanges
Address
Loree des Mas, Avenue du golf, Baillargues, Montpellier, FRA, 34670
Medesis Pharma SA is a clinical development stage biopharmaceutical company. It is engaged in the development of orally administered molecule drug candidates to expand therapeutic usefulness to address major unmet medical needs.

Medesis Pharma Headlines

No Headlines